Legend Biotech Co. to Post Q2 2023 Earnings of ($0.34) Per Share, HC Wainwright Forecasts (NASDAQ:LEGN)

Legend Biotech Co. (NASDAQ:LEGN – Get Rating) – Analysts at HC Wainwright lifted their Q2 2023 earnings estimates for Legend Biotech in a research report issued to clients and investors on Tuesday, June 6th. HC Wainwright analyst M. Kapoor now expects that the company will earn ($0.34) per share for the quarter, up from their […]

Related Keywords

United States ,China ,Canada ,American ,William Blair ,Jpmorgan Chase Co ,Macquarie Group Ltd ,Legend Biotech Corporation ,China Universal Asset Management Co ,American International Group Inc ,Ci Investments Inc ,Royal Bank ,Legend Biotech Co ,Nasdaq ,Legend Biotech Company Profile ,Lazard Asset Management ,Legend Biotech ,Get Rating ,Daiwa Capital Markets ,Biotech Trading Down ,International Group ,Asset Management ,Universal Asset Management ,Biotech Corporation ,Legend Biotech Daily ,Nasdaq Legn ,Legn ,Medical ,Earnings Estimates ,Hc Wainwright ,